Cargando…

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Detalles Bibliográficos
Autores principales:	Caocci, Giovanni, Mulas, Olga, Mantovani, Daniela, Costa, Alessandro, Galizia, Andrea, Barabino, Luca, Greco, Marianna, Murru, Roberta, La Nasa, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308065/ https://www.ncbi.nlm.nih.gov/pubmed/34302519 http://dx.doi.org/10.1007/s00277-021-04613-w

Ejemplares similares

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
por: Caocci, Giovanni, et al.
Publicado: (2021)

Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine
por: Galitzia, Andrea, et al.
Publicado: (2022)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination
por: Caocci, Giovanni, et al.
Publicado: (2021)

Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
por: Caocci, Giovanni, et al.
Publicado: (2020)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
por: Amodio, Donato, et al.
Publicado: (2021)

Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres
por: Innocenti, Idanna, et al.
Publicado: (2022)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan
por: Nishikimi, Akihiko, et al.
Publicado: (2023)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
por: Greco, Marilena, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
por: Chan, Amanda CY., et al.
Publicado: (2021)

Reactive arthritis following COVID-19 vaccination with BNT162b2
por: Lebowitz, Emily, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients
por: Ducloux, Didier, et al.
Publicado: (2021)

Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty(®))
por: Held, Jürgen, et al.
Publicado: (2021)

Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status
por: Ducloux, Didier, et al.
Publicado: (2021)

Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
por: Gallais, Floriane, et al.
Publicado: (2022)

PB2236: HUMORAL RESPONSE TO SARS-COV-2 VACCINATION WITH BNT162B2 COVID-19 MRNA IN PATIENTS WITH HAEMOGLOBINOPATHIES
por: Giatagantzidou, I., et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ee2mp094kfimm08cd0bmof7en